Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Rachel S. Leibman"'
Autor:
Srujana S. Yadavalli, Jeffrey N. Carey, Rachel S. Leibman, Annie I. Chen, Andrew M. Stern, Manuela Roggiani, Andrew M. Lippa, Mark Goulian
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
The PhoQ/PhoP system regulates antimicrobial peptide defense in bacteria. Here the authors show that at sublethal concentrations of antimicrobial peptides, PhoPQ induces QueE, that then localizes to the divisome and blocks cell division independently
Externí odkaz:
https://doaj.org/article/745de4a346bf49efb45df9d57737e76a
Publikováno v:
mBio, Vol 3, Iss 4 (2012)
ABSTRACT Enterococcus faecalis is a common Gram-positive commensal bacterium of the metazoan gastrointestinal tract capable of biofilm formation and an opportunistic pathogen of increasing clinical concern. Dogma has held that biofilms are slow-growi
Externí odkaz:
https://doaj.org/article/b551b2636adb4fd891c2f24387248241
Autor:
Derrick L. Dopkin, Xiaochuan Shan, James L. Riley, Kevin Gayout, Joshua Glover, Rachel S. Leibman, Colby R. Maldini, Joshua P. Mills
Publikováno v:
Molecular Therapy
Mol Ther
Mol Ther
HIV infection preferentially depletes HIV-specific CD4+ T cells, thereby impairing antiviral immunity. In this study, we explored the therapeutic utility of adoptively transferred CD4+ T cells expressing an HIV-specific chimeric antigen receptor (CAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2a3c9d36f15298a119e3a9abe9d2f4
https://doi.org/10.1016/j.ymthe.2020.05.012
https://doi.org/10.1016/j.ymthe.2020.05.012
Autor:
Jordi Bruix, Talia Golan, Gregory Vosganian, Kathy D. Miller, Anthony W. Tolcher, Susan Lacy, Satwant Lally, Toshio Shimizu, Arjun Vasant Balar, Stacie Lambert, John D. Powderly, Martha Elizabeth Blaney, Xiaowen Guan, Rachel S Leibman, Patricia LoRusso, Albiruni Ryan Abdul Razak, Loren S. Michel
Publikováno v:
Cancer Research. 81:CT207-CT207
Background Glycoprotein-A repetitions predominant (GARP) regulates membrane-bound transforming growth factor β1 (TGFβ1), an immunosuppressive cytokine. ABBV-151 is a first-in-class monoclonal antibody (mAb) that binds to the GARP-TGFβ1 complex and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::364f5a4c8f04997c92b89ba73dc652f9
https://doi.org/10.1158/1538-7445.am2021-ct207
https://doi.org/10.1158/1538-7445.am2021-ct207
Autor:
Maria Kovalenko, Toshio Shimizu, Junichiro Yuda, Kevin J. Freise, Pierre Peterlin, Yakir Moshe, Stacy Jaryno, Nashat Y. Gabrail, Esma Saada-Bouzid, Bruno Quesnel, William R Henner, Rachel S Leibman, Apurvasena Parikh, Donghui Huang, Abraham Avigdor, Mor Moskovitz, Edward B. Reilly
Publikováno v:
Journal of Clinical Oncology. 39:TPS2674-TPS2674
TPS2674 Background: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive therapeutic target in cancer, due to its broad expression in solid tumors and hematologic malignancies but limited expression in normal tissues. Ele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::311713fa118f0bd0dce9a193e77e47f2
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2674
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2674
Autor:
Manuela Roggiani, Andrew M. Stern, Srujana S. Yadavalli, Jeffrey N. Carey, Annie I. Chen, Mark Goulian, Rachel S. Leibman, Andrew M. Lippa
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
Nature Communications
Nature Communications
Antimicrobial peptides are an important component of the molecular arsenal employed by hosts against bacteria. Many bacteria in turn possess pathways that provide protection against these compounds. In Escherichia coli and related bacteria, the PhoQ/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ad46cf51d3c54948293d20a337b5a9
https://doaj.org/article/745de4a346bf49efb45df9d57737e76a
https://doaj.org/article/745de4a346bf49efb45df9d57737e76a
Autor:
Kathy D. Miller, Stacie Lambert, Albiruni Ryan Abdul Razak, Satwant Lally, Talia Golan, Toshio Shimizu, Arjun Vasant Balar, Jordi Bruix, Anthony W. Tolcher, Patricia LoRusso, Rachel S Leibman, Susan Lacy, John D. Powderly, Martha Elizabeth Blaney, Loren S. Michel, Gregory Vosganian, X. Guan
Publikováno v:
Annals of Oncology. 31:S499
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2723b40ae7fe5202ceb946dcbe5bc16
https://doi.org/10.1016/j.annonc.2020.08.710
https://doi.org/10.1016/j.annonc.2020.08.710
Autor:
Rachel S. Leibman, James L. Riley
Publikováno v:
Molecular Therapy. 23:1149-1159
Despite the ability of antiretroviral therapy to minimize human immunodeficiency virus type 1 (HIV-1) replication and increase the duration and quality of patients' lives, the health consequences and financial burden associated with the lifelong trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::071e755920ab9089578b6b54f69b507e
https://doi.org/10.1038/mt.2015.70
https://doi.org/10.1038/mt.2015.70
Autor:
James L. Riley, Ronald G. Collman, Joshua Glover, Simon F. Lacey, Christoph T. Ellebrecht, Keith A. Dufendach, Colby R. Maldini, Yanjie Yi, Irina Kulikovskaya, Farida Shaheen, Michael C. Holmes, Anthony Secreto, Jianbin Wang, Aimee S. Payne, Rachel S. Leibman, Sarah R. Akkina, Max W. Richardson
Publikováno v:
PLoS Pathogens, Vol 13, Iss 10, p e1006613 (2017)
PLoS Pathogens
PLoS Pathogens
HIV is adept at avoiding naturally generated T cell responses; therefore, there is a need to develop HIV-specific T cells with greater potency for use in HIV cure strategies. Starting with a CD4-based chimeric antigen receptor (CAR) that was previous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c38ff7742cb4d715179ba71d3d3f0233
https://doaj.org/article/942f579e40144a97893d9fb154526278
https://doaj.org/article/942f579e40144a97893d9fb154526278
Autor:
Masayuki Takeda, Masayuki Shintani, Hibiki Udagawa, Isamu Okamoto, Ikuko Yasuda, Tomohide Tamura, Hiroaki Akamatsu, Charity D. Scripture, Shunsuke Teraoka, Rachel S Leibman, Kentaro Tanaka, Keisuke Kirita, Sumiko Okubo, Kazuhiko Nakagawa, Shintaro Kanda, Yutaka Fujiwara
Publikováno v:
Journal of Clinical Oncology. 37:8557-8557
8557 Background: SCLC rapidly recurs after first-line platinum therapy, and while several agents are approved in the relapsed/refractory setting, there is no approved agent or existing standard of care for third-line in Japan. Rovalpituzumab tesirine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5f9e1fbdfde6f2411a5c0ba4d672da4
https://doi.org/10.1200/jco.2019.37.15_suppl.8557
https://doi.org/10.1200/jco.2019.37.15_suppl.8557